Regenerative Biologics Supplier for San Francisco Orthopedic Groups

How orthopedic groups vet a tissue and biologics vendor

Most orthopedic practices and ambulatory surgery centers treat a new biologics vendor the way they treat any new supply-chain relationship: documentation first, product second. Before a practice places a first order, our team typically fields requests for the certificate of analysis for the specific lot in question, a donor eligibility summary, and a lot release record showing the sterility testing and quarantine hold that preceded release.

Group purchasing or multi-location orthopedic organizations in San Francisco often add a step: routing the documentation through a compliance officer or practice administrator before a physician signs off on the account. We support that process by making the same documentation set available to every verified account, not a subset reserved for larger buyers.

NPI verification and account setup

Accounts are opened only for licensed physicians and for clinics ordering under physician supervision. Setup starts with an NPI number, which we use to confirm the ordering party is a credentialed provider before any product ships. A practice administrator can initiate the request, but the account itself is tied to the supervising physician of record.

Once verified, an account can request peer-to-peer calls with our team to walk through product documentation, lot structure, and how traceability is maintained after delivery. These conversations are limited to sourcing and documentation; they are not clinical guidance on use, dosing, or procedure.

Cold-chain handling for shipments into Northern California

Cryopreserved Wharton's jelly and exosome formats ship overnight on dry ice in validated containers and are held at -80 degrees Celsius prior to shipment. For a San Francisco receiving location, that means planning for a defined delivery window and having a freezer ready at intake rather than treating the shipment like standard mail. Lyophilized formats are shelf-stable and do not require the same cold-chain receiving step, though they still arrive with lot-specific handling instructions.

Every unit carries a unique lot identifier, and we recommend logging that identifier against the patient record at the point of use so the practice can trace any unit back to its source lot if a question arises later.

Confirming regulatory classification with your own counsel

Whether a given Wharton's jelly product and intended use falls within the minimal-manipulation, homologous-use framework for HCT/Ps is a determination the practice and its legal counsel need to make, not something we can certify on a vendor's behalf. Exosome products are a separate category: there are currently no FDA-approved exosome products, and these are generally regulated as biologic drugs rather than under the 361 HCT/P framework.

We recommend San Francisco practices confirm their intended use and marketing claims with the California medical board and their own healthcare counsel before adoption, particularly given increased 2026 FDA enforcement attention toward distributor and clinic websites in this category.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.